Illness characteristics of patients in clinical drug studies of mania

C. L. Bowden, J. R. Calabrese, B. A. Wallin, A. C. Swann, S. L. McElroy, S. C. Risch, R. M A Hirschfeld

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Two recent large-scale studies of the effectiveness and safety of divalproex versus lithium and placebo in the manic phase of bipolar disorder have provided an opportunity to investigate the characteristics of patients enrolled in clinical drug trials of mood stabilizers. Both studies are randomized, double-blind, parallel-group, multicenter trials; the first addresses effectiveness in acute mania, and the second addresses effectiveness in prevention of manic episodes. Date on demographic, illness severity, and treatment response characteristics were compared between Study 1 and six other clinical drug trials in acute mania from the pat decade that had data in comparable domains. Although patients experienced onset of bipolar disorder in their early twenties, the average age of enrollment in the studies was about 40. Approximately equal numbers of men end women ware enrolled. The patients were severely ill at the time of enrollment, with mean scores on the Global Assessment Scale ranging from 29 to 37. Overall, characteristics were remarkably similar across studies and representative of those reported in epidemiological studies. From Study 2, which is currently in progress, characteristics of patients recruited into the trial wars determined. At least 10 subjects wars initially assessed for each subject actually enrolled in the trial. The two factors most associated with failure to move from the open phase of the study to the randomized phase were administrative problems (principally failure of subjects to adhere to the medication regimen and protocol requirements) and inability, even with an open treatment protocol, to achieve adequate recovery from the index manic episode within 3 months.

Original languageEnglish (US)
Pages (from-to)103-109
Number of pages7
JournalPsychopharmacology Bulletin
Volume31
Issue number1
StatePublished - 1995

Fingerprint

Bipolar Disorder
Pharmaceutical Preparations
Clinical Trials
Valproic Acid
Clinical Protocols
Lithium
Double-Blind Method
Multicenter Studies
Epidemiologic Studies
Placebos
Demography
Safety
Clinical Studies
Warfare
Therapeutics

Keywords

  • bipolar
  • eligibility
  • mania
  • patients
  • severity

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Bowden, C. L., Calabrese, J. R., Wallin, B. A., Swann, A. C., McElroy, S. L., Risch, S. C., & Hirschfeld, R. M. A. (1995). Illness characteristics of patients in clinical drug studies of mania. Psychopharmacology Bulletin, 31(1), 103-109.

Illness characteristics of patients in clinical drug studies of mania. / Bowden, C. L.; Calabrese, J. R.; Wallin, B. A.; Swann, A. C.; McElroy, S. L.; Risch, S. C.; Hirschfeld, R. M A.

In: Psychopharmacology Bulletin, Vol. 31, No. 1, 1995, p. 103-109.

Research output: Contribution to journalArticle

Bowden, CL, Calabrese, JR, Wallin, BA, Swann, AC, McElroy, SL, Risch, SC & Hirschfeld, RMA 1995, 'Illness characteristics of patients in clinical drug studies of mania', Psychopharmacology Bulletin, vol. 31, no. 1, pp. 103-109.
Bowden CL, Calabrese JR, Wallin BA, Swann AC, McElroy SL, Risch SC et al. Illness characteristics of patients in clinical drug studies of mania. Psychopharmacology Bulletin. 1995;31(1):103-109.
Bowden, C. L. ; Calabrese, J. R. ; Wallin, B. A. ; Swann, A. C. ; McElroy, S. L. ; Risch, S. C. ; Hirschfeld, R. M A. / Illness characteristics of patients in clinical drug studies of mania. In: Psychopharmacology Bulletin. 1995 ; Vol. 31, No. 1. pp. 103-109.
@article{6cb1f280bea943d1b191ef1c6d71ae37,
title = "Illness characteristics of patients in clinical drug studies of mania",
abstract = "Two recent large-scale studies of the effectiveness and safety of divalproex versus lithium and placebo in the manic phase of bipolar disorder have provided an opportunity to investigate the characteristics of patients enrolled in clinical drug trials of mood stabilizers. Both studies are randomized, double-blind, parallel-group, multicenter trials; the first addresses effectiveness in acute mania, and the second addresses effectiveness in prevention of manic episodes. Date on demographic, illness severity, and treatment response characteristics were compared between Study 1 and six other clinical drug trials in acute mania from the pat decade that had data in comparable domains. Although patients experienced onset of bipolar disorder in their early twenties, the average age of enrollment in the studies was about 40. Approximately equal numbers of men end women ware enrolled. The patients were severely ill at the time of enrollment, with mean scores on the Global Assessment Scale ranging from 29 to 37. Overall, characteristics were remarkably similar across studies and representative of those reported in epidemiological studies. From Study 2, which is currently in progress, characteristics of patients recruited into the trial wars determined. At least 10 subjects wars initially assessed for each subject actually enrolled in the trial. The two factors most associated with failure to move from the open phase of the study to the randomized phase were administrative problems (principally failure of subjects to adhere to the medication regimen and protocol requirements) and inability, even with an open treatment protocol, to achieve adequate recovery from the index manic episode within 3 months.",
keywords = "bipolar, eligibility, mania, patients, severity",
author = "Bowden, {C. L.} and Calabrese, {J. R.} and Wallin, {B. A.} and Swann, {A. C.} and McElroy, {S. L.} and Risch, {S. C.} and Hirschfeld, {R. M A}",
year = "1995",
language = "English (US)",
volume = "31",
pages = "103--109",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "1",

}

TY - JOUR

T1 - Illness characteristics of patients in clinical drug studies of mania

AU - Bowden, C. L.

AU - Calabrese, J. R.

AU - Wallin, B. A.

AU - Swann, A. C.

AU - McElroy, S. L.

AU - Risch, S. C.

AU - Hirschfeld, R. M A

PY - 1995

Y1 - 1995

N2 - Two recent large-scale studies of the effectiveness and safety of divalproex versus lithium and placebo in the manic phase of bipolar disorder have provided an opportunity to investigate the characteristics of patients enrolled in clinical drug trials of mood stabilizers. Both studies are randomized, double-blind, parallel-group, multicenter trials; the first addresses effectiveness in acute mania, and the second addresses effectiveness in prevention of manic episodes. Date on demographic, illness severity, and treatment response characteristics were compared between Study 1 and six other clinical drug trials in acute mania from the pat decade that had data in comparable domains. Although patients experienced onset of bipolar disorder in their early twenties, the average age of enrollment in the studies was about 40. Approximately equal numbers of men end women ware enrolled. The patients were severely ill at the time of enrollment, with mean scores on the Global Assessment Scale ranging from 29 to 37. Overall, characteristics were remarkably similar across studies and representative of those reported in epidemiological studies. From Study 2, which is currently in progress, characteristics of patients recruited into the trial wars determined. At least 10 subjects wars initially assessed for each subject actually enrolled in the trial. The two factors most associated with failure to move from the open phase of the study to the randomized phase were administrative problems (principally failure of subjects to adhere to the medication regimen and protocol requirements) and inability, even with an open treatment protocol, to achieve adequate recovery from the index manic episode within 3 months.

AB - Two recent large-scale studies of the effectiveness and safety of divalproex versus lithium and placebo in the manic phase of bipolar disorder have provided an opportunity to investigate the characteristics of patients enrolled in clinical drug trials of mood stabilizers. Both studies are randomized, double-blind, parallel-group, multicenter trials; the first addresses effectiveness in acute mania, and the second addresses effectiveness in prevention of manic episodes. Date on demographic, illness severity, and treatment response characteristics were compared between Study 1 and six other clinical drug trials in acute mania from the pat decade that had data in comparable domains. Although patients experienced onset of bipolar disorder in their early twenties, the average age of enrollment in the studies was about 40. Approximately equal numbers of men end women ware enrolled. The patients were severely ill at the time of enrollment, with mean scores on the Global Assessment Scale ranging from 29 to 37. Overall, characteristics were remarkably similar across studies and representative of those reported in epidemiological studies. From Study 2, which is currently in progress, characteristics of patients recruited into the trial wars determined. At least 10 subjects wars initially assessed for each subject actually enrolled in the trial. The two factors most associated with failure to move from the open phase of the study to the randomized phase were administrative problems (principally failure of subjects to adhere to the medication regimen and protocol requirements) and inability, even with an open treatment protocol, to achieve adequate recovery from the index manic episode within 3 months.

KW - bipolar

KW - eligibility

KW - mania

KW - patients

KW - severity

UR - http://www.scopus.com/inward/record.url?scp=0029162239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029162239&partnerID=8YFLogxK

M3 - Article

C2 - 7675973

AN - SCOPUS:0029162239

VL - 31

SP - 103

EP - 109

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 1

ER -